Omeros reports Q1 EPS (54c) with items, consensus (45c)
moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring next, click here to view […]
OMER
OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring next, click here to view […]
Omeros Corporation Reports First Quarter 2014 Financial Results
[PR Newswire] – SEATTLE, May 12, 2014 /PRNewswire/ — Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics … moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring next, click here to view […]
4:37 pm Omeros announces proposed public offering of common stock, size not disclosed
moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring next, click here to view […]
7:05 am Omeros announces positive OMS721 data in serum from patients with aHUS
moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring next, click here to view […]
Additional Positive Data on Omeros Treatment
moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring next, click here to view […]
7:04 am Omeros submits IND to advance OMS721 Phase 2 clinical program
moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring next, click here to view […]
Omeros to Present at Cowen and Company 34th Annual Health Care Conference
[PR Newswire] – SEATTLE, Feb. 26, 2014 /PRNewswire/ — Omeros Corporation (OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring next, click here to view […]
Omeros Doses First Patient in a Study
moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring next, click here to view […]
Omeros Announces Enrollment in Second Phase 2 Clinical Trial with OMS824
[PR Newswire] – SEATTLE, Feb. 19, 2014 /PRNewswire/ — Omeros Corporation (OMER) today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company’s phosphodiesterase 10 (PDE10) inhibitor being developed for the treatm moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring […]
